NovaQuest Capital to buy Viamet Pharmaceuticals

This article was originally published here

NovaQuest Capital Management has agreed to acquire Viamet Pharmaceuticals, including its product candidate, VT-1161, which has completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply